Annual Current Liabilities
$63.26 M
+$28.73 M+83.17%
December 31, 2023
Summary
- As of February 8, 2025, EYPT annual total current liabilities is $63.26 million, with the most recent change of +$28.73 million (+83.17%) on December 31, 2023.
- During the last 3 years, EYPT annual current liabilities has risen by +$48.38 million (+324.93%).
- EYPT annual current liabilities is now at all-time high.
Performance
EYPT Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$48.79 M
-$13.31 M-21.43%
September 30, 2024
Summary
- As of February 8, 2025, EYPT quarterly total current liabilities is $48.79 million, with the most recent change of -$13.31 million (-21.43%) on September 30, 2024.
- Over the past year, EYPT quarterly current liabilities has dropped by -$15.10 million (-23.64%).
- EYPT quarterly current liabilities is now -29.20% below its all-time high of $68.92 million, reached on June 30, 2023.
Performance
EYPT Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
EYPT Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +83.2% | -23.6% |
| 3 y3 years | +324.9% | +41.3% |
| 5 y5 years | +194.8% | +41.3% |
EYPT Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +167.4% | -29.2% | +106.3% |
| 5 y | 5-year | at high | +449.2% | -29.2% | +409.0% |
| alltime | all time | at high | >+9999.0% | -29.2% | +8192.7% |
EyePoint Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $48.79 M(-21.4%) |
| Jun 2024 | - | $62.10 M(-0.8%) |
| Mar 2024 | - | $62.58 M(-1.1%) |
| Dec 2023 | $63.26 M(+83.2%) | $63.26 M(-1.0%) |
| Sep 2023 | - | $63.90 M(-7.3%) |
| Jun 2023 | - | $68.92 M(+153.0%) |
| Mar 2023 | - | $27.24 M(-21.1%) |
| Dec 2022 | $34.54 M(+46.0%) | $34.54 M(+0.8%) |
| Sep 2022 | - | $34.26 M(+2.6%) |
| Jun 2022 | - | $33.39 M(+4.4%) |
| Mar 2022 | - | $31.97 M(+35.1%) |
| Dec 2021 | $23.66 M(+58.9%) | $23.66 M(+18.7%) |
| Sep 2021 | - | $19.93 M(+22.7%) |
| Jun 2021 | - | $16.25 M(+20.9%) |
| Mar 2021 | - | $13.44 M(-9.7%) |
| Dec 2020 | $14.89 M(+29.2%) | $14.89 M(+15.2%) |
| Sep 2020 | - | $12.93 M(+34.9%) |
| Jun 2020 | - | $9.59 M(-6.9%) |
| Mar 2020 | - | $10.30 M(-10.6%) |
| Dec 2019 | $11.52 M(-46.3%) | $11.52 M(+11.1%) |
| Sep 2019 | - | $10.37 M(-3.3%) |
| Jun 2019 | - | $10.72 M(-56.5%) |
| Mar 2019 | - | $24.66 M(+10.0%) |
| Dec 2018 | $21.46 M(-0.9%) | - |
| Sep 2018 | - | $22.42 M(+3.5%) |
| Jun 2018 | $21.66 M(+309.5%) | $21.66 M(+2.1%) |
| Mar 2018 | - | $21.21 M(+399.2%) |
| Dec 2017 | - | $4.25 M(-0.7%) |
| Sep 2017 | - | $4.28 M(-19.1%) |
| Jun 2017 | $5.29 M(+3.9%) | $5.29 M(+7.1%) |
| Mar 2017 | - | $4.94 M(+0.3%) |
| Dec 2016 | - | $4.93 M(+1.8%) |
| Sep 2016 | - | $4.84 M(-4.9%) |
| Jun 2016 | $5.09 M(+52.1%) | $5.09 M(+28.4%) |
| Mar 2016 | - | $3.97 M(+2.2%) |
| Dec 2015 | - | $3.88 M(+29.7%) |
| Sep 2015 | - | $2.99 M(-10.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | $3.35 M(+57.5%) | $3.35 M(+50.9%) |
| Mar 2015 | - | $2.22 M(-2.4%) |
| Dec 2014 | - | $2.27 M(-1.7%) |
| Sep 2014 | - | $2.31 M(+8.7%) |
| Jun 2014 | $2.13 M(-35.6%) | $2.13 M(-6.6%) |
| Mar 2014 | - | $2.28 M(+5.8%) |
| Dec 2013 | - | $2.15 M(-24.7%) |
| Sep 2013 | - | $2.86 M(-13.5%) |
| Jun 2013 | $3.30 M(+3.9%) | $3.30 M(+23.0%) |
| Mar 2013 | - | $2.69 M(+28.9%) |
| Dec 2012 | - | $2.08 M(-39.8%) |
| Sep 2012 | - | $3.46 M(+8.9%) |
| Jun 2012 | $3.18 M(-36.8%) | $3.18 M(+22.8%) |
| Mar 2012 | - | $2.59 M(-1.7%) |
| Dec 2011 | - | $2.63 M(-34.0%) |
| Sep 2011 | - | $3.99 M(-20.6%) |
| Jun 2011 | $5.03 M(+71.5%) | $5.03 M(+237.3%) |
| Mar 2011 | - | $1.49 M(-35.8%) |
| Sep 2010 | - | $2.32 M(-20.8%) |
| Jun 2010 | $2.93 M(-66.3%) | $2.93 M(-22.4%) |
| Mar 2010 | - | $3.78 M(-5.8%) |
| Dec 2009 | - | $4.01 M(-44.7%) |
| Sep 2009 | - | $7.26 M(-16.7%) |
| Jun 2009 | $8.72 M(-49.5%) | $8.72 M(-20.9%) |
| Mar 2009 | - | $11.02 M(-15.9%) |
| Dec 2008 | - | $13.11 M(-3.3%) |
| Sep 2008 | - | $13.55 M(-21.6%) |
| Jun 2008 | $17.28 M(+3.1%) | $17.28 M(+8.7%) |
| Mar 2008 | - | $15.90 M(+42.1%) |
| Dec 2007 | - | $11.19 M(-13.3%) |
| Sep 2007 | - | $12.90 M(-23.0%) |
| Jun 2007 | $16.76 M(-5.8%) | $16.76 M(-29.9%) |
| Dec 2006 | - | $23.89 M(+34.3%) |
| Jun 2006 | $17.79 M(+1044.2%) | $17.79 M(+1044.2%) |
| Jun 2005 | $1.55 M(+15.5%) | $1.55 M(+15.5%) |
| Jun 2004 | $1.35 M(+128.9%) | $1.35 M(+128.9%) |
| Jun 2003 | $588.40 K(+303.8%) | $588.40 K |
| Jun 2001 | $145.70 K | - |
FAQ
- What is EyePoint Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual current liabilities year-on-year change?
- What is EyePoint Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly current liabilities year-on-year change?
What is EyePoint Pharmaceuticals annual total current liabilities?
The current annual current liabilities of EYPT is $63.26 M
What is the all time high annual current liabilities for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual total current liabilities is $63.26 M
What is EyePoint Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, EYPT annual total current liabilities has changed by +$28.73 M (+83.17%)
What is EyePoint Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of EYPT is $48.79 M
What is the all time high quarterly current liabilities for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly total current liabilities is $68.92 M
What is EyePoint Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, EYPT quarterly total current liabilities has changed by -$15.10 M (-23.64%)